Chlamydia Grade 2 (DAG-H10357)

Nature
Native
Tag/Conjugate
Unconjugated
Preparation
Mouse L cells are infected with C. trachomatis elementary bodies. Optimally infected cells are harvested and disrupted by sonication in PBS. Cellular debris is removed using centrifugation.
Procedure
None
Size
1 mL;10 mL
Buffer
PBS
Preservative
None
Storage
Store this antigen preparation frozen at -70 °C to -100 °C. Repeated freezing and thawing should be avoided.
Introduction
Chlamydia trachomatis, an obligate intracellular human pathogen, is one of four bacterial species in the genus Chlamydia. C. trachomatis is a gram-negative bacterium, therefore its cell wall components retain the counter-stain safranin and appear pink under a light microscope. It can appear as either coccoid or rod shape.
Antigen Description
Chlamydia grade 2 antigen contains a high concentration of elementary bodies and chlamydia!
components in PBS. The preparation contains no preservative or detergent. Residual host cellular material is present
Keywords
C.trachomatis; Chlamydia trachomatis
Inactivation
This antigen preparation is inactivated using gamma radiation. This procedure is effective primarily by damaging chlamydia!genetic material.

Citations


Have you cited DAG-H10357 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Authors: Lai, Chih-Cheng; Wang, Cheng-Yi; Hsueh, Po-Ren

Co-infection has been reported in patients with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, but there is limited knowledge on co-infection among patients with coronavirus disease 2019 (COVID-19). The prevalence of co-infection was variable among COVID-19 patients in different studies, however, it could be up to 50% among non-survivors. Co-pathogens included bacteria, such as Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumonia, Legionella pneumophila and Acinetobacter baumannii; Candida species and Aspergillus flavus; and viruses such as influenza, coronavirus, rhinovirus/enterovirus, parainfluenza, metapneumovirus, influenza B virus, and human immunodeficiency virus. Influenza A was one of the most common co-infective viruses, which may have caused initial false-negative results of real-time reverse-transcriptase polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Laboratory and imaging findings alone cannot help distinguish co-infection from SARS-CoV-2 infection. Newly developed syndromic multiplex panels that incorporate SARS-CoV-2 may facilitate the early detection of co-infection among COVID-19 patients. By contrast, clinicians cannot rule out SARS-CoV-2 infection by ruling in other respiratory pathogens through old syndromic multiplex panels at this stage of the COVID-19 pandemic. Therefore, clinicians must have a high index of suspicion for coinfection among COVID-19 patients. Clinicians can neither rule out other co-infections caused by respiratory pathogens by diagnosing SARS-CoV-2 infection nor rule out COVID-19 by detection of non-SARS-CoV-2 respiratory pathogens. After recognizing the possible pathogens causing co-infection among COVID-19 patients, appropriate antimicrobial agents can be recommended. Copyright (C) 2020, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.

Attitudes of women participating in a clinical trial on point-of-care testing and home testing for STIs

INTERNATIONAL JOURNAL OF STD & AIDS

Authors: Chow, Karen; Edi, Rina; Gin, Geneen; Morris, Sheldon R.

Neisseria gonorrhoeae,Chlamydia trachomatisandTrichomonas vaginalisinfections are a public health concern and cost the United States' healthcare system 16 billion dollars annually. By minimizing barriers to testing, an increased number of infections can be detected and treated. A home-based point-of-care (POC) sexually transmitted infection (STI) test may reduce personal, structural, social and system-level barriers to STI testing. This study assesses patient preferences and acceptance of home-based POC STI testing. We performed a cross-sectional, single-visit study of women aged 18 years and older at a single site. Women completed an anonymous online survey evaluating interest in POC STI testing, comfort in self-collecting vaginal swabs and participant reaction to a positive STI result. 138 participants completed the anonymous online survey. The survey results indicate high acceptability with self-collection of samples and home POC STI testing. A majority of participants were interested or very interested in a home POC STI device-especially amongst women with a past history of a STI. If receiving a positive test result, participants indicated they would want to have someone to discuss their results with, most preferring to speak with their primary care provider. Women on lower incomes were less comfortable and less interested with home testing. Women are likely to be receptive to home POC STI testing. Adapting to home-based testing will require engagement of primary care providers for management and surveillance of STIs.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket